HC Wainwright Has Pessimistic View of Kamada FY2025 Earnings

Kamada Ltd. (NASDAQ:KMDA) – Equities research analysts at HC Wainwright lowered their FY2025 earnings per share (EPS) estimates for shares of Kamada in a report released on Tuesday, November 11th. HC Wainwright analyst A. Fein now expects that the biotechnology company will post earnings of $0.38 per share for the year, down from their prior forecast of $0.47. The consensus estimate for Kamada’s current full-year earnings is $0.23 per share. HC Wainwright also issued estimates for Kamada’s Q4 2025 earnings at $0.10 EPS.

Separately, Weiss Ratings reiterated a “buy (b-)” rating on shares of Kamada in a research note on Wednesday, October 8th. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $13.00.

Kamada Stock Up 3.1%

Kamada stock opened at $7.28 on Thursday. The firm has a 50 day moving average price of $6.90 and a 200-day moving average price of $7.08. Kamada has a twelve month low of $5.54 and a twelve month high of $9.15. The company has a market capitalization of $418.64 million, a P/E ratio of 21.41, a P/E/G ratio of 0.70 and a beta of 0.81.

Kamada (NASDAQ:KMDA) last posted its quarterly earnings data on Monday, November 10th. The biotechnology company reported $0.09 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.01). The company had revenue of $47.01 million for the quarter, compared to analysts’ expectations of $154.21 million. Kamada had a return on equity of 7.41% and a net margin of 11.22%. Kamada has set its FY 2025 guidance at EPS.

Hedge Funds Weigh In On Kamada

A number of large investors have recently modified their holdings of the company. ARK Investment Management LLC purchased a new stake in Kamada in the 2nd quarter worth approximately $1,972,000. Goldman Sachs Group Inc. bought a new position in shares of Kamada in the first quarter worth $497,000. Huntleigh Advisors Inc. raised its position in shares of Kamada by 3.9% in the second quarter. Huntleigh Advisors Inc. now owns 135,776 shares of the biotechnology company’s stock worth $1,052,000 after buying an additional 5,151 shares in the last quarter. Trexquant Investment LP bought a new stake in Kamada during the first quarter valued at $82,000. Finally, JPMorgan Chase & Co. grew its position in Kamada by 43.6% during the third quarter. JPMorgan Chase & Co. now owns 40,984 shares of the biotechnology company’s stock worth $284,000 after buying an additional 12,442 shares in the last quarter. 20.38% of the stock is currently owned by institutional investors.

About Kamada

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.